Internal Medicine, Medical Oncology · Ocala, FL
NPI
1447755830
Since 2018
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
4945 SW 49th Pl
Ocala, FL, 34474
Phone (352) 237-9430
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
77,770 services
Medicare patients, 2024
682
Average age 76
Drug cost, 2024
$1.4M
397 prescriptions
Company payments, 2025
$3,799
From 45 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Francis P Matuszak was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 11,220 times for 16 patients. In total Francis P Matuszak billed 77,770 services in 130 codes, and Medicare paid $1.2M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-07-15.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 11,220 | 16 | $0.26 | $2,940 |
| J0897 Injection, denosumab, 1 mg | Office | 7,980 | 119 | $21.41 | $171K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,400 | 14 | $16.37 | $23K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 1,230 | 17 | $6.21 | $7,639 |
| 36415 Venipuncture Blood Collection | Office | 574 | 402 | $8.65 | $4,965 |
| 85025 Blood Count | Office | 532 | 341 | $7.61 | $4,049 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 460 | 21 | $0.09 | $40.52 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 439 | 14 | $0.23 | $103 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 370 | 17 | $0.61 | $224 |
| 96372 Injection Administration | Office | 345 | 235 | $10.83 | $3,737 |
| Q5127 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | Office | 312 | 16 | $250.40 | $78K |
| 99213 Office E&M - Established | Office | 162 | 145 | $70.10 | $11K |
| 96375 Injection Administration | Office | 142 | 46 | $11.50 | $1,633 |
| 96413 Chemotherapy Administration | Office | 122 | 49 | $96.58 | $12K |
| 99214 Office E&M - Established | Office | 114 | 78 | $97.73 | $11K |
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 574 | 402 | $8.65 | $4,965 |
| 85025 Blood Count | 532 | 341 | $7.61 | $4,049 |
| 85045 Blood Count | 21 | 17 | $3.91 | $82.11 |
Medicare prescription drug claims, 2024
In 2024, the drug Francis P Matuszak prescribed most often to Medicare patients was Diphenhydramine Hcl, with 29 prescriptions and refills. In total Francis P Matuszak wrote 397 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Diphenhydramine Hcl Generic | 29 | 35 | Under 11 | $52.77 |
| Revlimid Lenalidomide | 26 | 26 | Under 11 | $371K |
| Ondansetron Hcl Ondansetron Hcl/Pf | 24 | 24 | Under 11 | $34.28 |
| Xgeva Denosumab | 20 | 20 | Under 11 | $64K |
| Dexamethasone Sodium Phosphate Generic | 19 | 25 | Under 11 | $58.68 |
| Anastrozole Generic | 15 | 39 | Under 11 | $320 |
| Eliquis Apixaban | 14 | 16 | Under 11 | $9,234 |
| Herceptin Trastuzumab | 14 | 14 | Under 11 | $86K |
| Acyclovir Generic | 14 | 18 | Under 11 | $179 |
| Ondansetron Odt Ondansetron | 14 | 14 | Under 11 | $277 |
| Dexamethasone Generic | 13 | 13 | Under 11 | $357 |
| Opdivo Nivolumab | 13 | 13 | Under 11 | $186K |
Brand drugs: 147 claims; generic drugs: 250 claims; opioid claims: 17.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Francis P Matuszak $3,799 ($3,799 in general payments such as food, travel and fees) from 45 companies. The largest payer was Novartis Pharmaceuticals Corporation with $790.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 23 | $790 |
| AstraZeneca Pharmaceuticals LP AZN | 12 | $293 |
| Celgene Corporation BMY | 11 | $232 |
| Pfizer Inc. PFE | 13 | $224 |
| Daiichi Sankyo Inc. 4568.T | 11 | $190 |
| Regeneron Healthcare Solutions, Inc. REGN | 6 | $163 |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $123 |
| Merck Sharp & Dohme LLC MRK | 5 | $103 |
| Seagen Inc. PFE | 1 | $99.99 |
| Janssen Biotech, Inc. JNJ | 4 | $94.04 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.